ArticleMicrobiology spectrum2025
High level non-carbapenemase carbapenem resistance by overlaying mutations of
Abstract read
In one paragraph
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Multifaceted effects ofVirulence · 2026Article
- Targeting Outer Membrane Vesicles ofJournal of microbiology and biotechnology · 2026Review
- Molecular determinants associated with resistance to imipenem and imipenem-relebactam in clinical Pseudomonas aeruginosa isolates.BMC genomics · 2026Article
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Identification of a novel gene inAntimicrobial agents and chemotherapy · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- The Burden of Antimicrobial-Resistant Pseudomonas aeruginosa Isolates in Children With Cystic Fibrosis: Molecular Characterization and Genotyping Analysis.MicrobiologyOpen · 2026Article
- Phylogenomic and phenotypic profiling of carbapenem-resistantMicrobial genomics · 2026Article
- Detection of carbapenem resistance among third-generation cephalosporin-resistant Enterobacterales from small-scale poultry farms in peri-urban Lusaka, Zambia.Access microbiology · 2026Article
- Genomic Epidemiology and Antimicrobial Resistance Analyses ofInfection and drug resistance · 2026Article
- Antimicrobial Resistance Trends, Resistance Mechanisms, and Antibiotic Consumption in COVID-19 Versus Non-COVID-19 Units: A Seven-Year Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Unveiling meropenem resistance and co-resistance patterns in Klebsiella pneumoniae and Acinetobacter baumannii: a global genome analysis using ML/DL and association mining.BMC microbiology · 2025Article
- Specific variants inMicrobiology spectrum · 2025Article
- Navigating an evolving microbial landscape: emerging antimicrobial resistance trends and precision stewardship in Tianjin tertiary hospitals (2021-2023).Frontiers in cellular and infection microbiology · 2025Article
- Resistance mechanisms and therapeutic strategies forTherapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Yan YangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0001-5369-2459
Xue LiBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Lang SunBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiu-Kun WangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
You-Wen ZhangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0002-3985-1393
Jing PangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0002-0538-0327
Guo-Qing LiBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xin-Xin HuBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Tong-Ying NieBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xin-Yi YangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jian-Hua Liu *Department of Respiratory Medicine, the First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Gerrit Brandis *Department of Cell and Molecular Biology (ICM), Uppsala University, Uppsala, Sweden.
Xue-Fu You *Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Cong-Ran Li *Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0002-7505-7525
Funding
MOST | National Natural Science Foundation of China (NSFC) 82273980MOST | National Natural Science Foundation of China (NSFC) 82330110, 32141003the CAMS Innovation Fund for Medical Sciences 2021-I2M-1-030the CAMS Innovation Fund for Medical Sciences 2021-I2M-1-039the National Mega-project for Innovative Drugs 2019ZX09721001the National Science and Technology Infrastructure of China NPRC-32
Abstract
Carbapenem-resistant IMPORTANCE: The emergence of carbapenem-resistant
Indexed as
Anti-Bacterial AgentsBacterial ProteinsCarbapenemsMicrobial Sensitivity TestsPorinsPseudomonas aeruginosaBacterial Outer Membrane Proteinsbeta-LactamasesDrug Resistance, BacterialHumansMembrane Transport ProteinsMeropenemMutationPseudomonas InfectionsRepressor ProteinsAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsMembrane Transport ProteinsMeropenemMexR protein, Pseudomonas aeruginosaOprD protein, Pseudomonas aeruginosaPorinsRepressor Proteinscarbapenem resistancein vivo evolutionoverlaying point mutationPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.